Brian Krex
About Brian Krex
Brian Krex serves as the General Counsel at KalVista Pharmaceuticals, Inc. since 2023 and has extensive experience in legal roles within the pharmaceutical industry, including positions at Alexion Pharmaceuticals and Pfizer.
Work at KalVista Pharmaceuticals
Brian Krex serves as General Counsel at KalVista Pharmaceuticals, Inc., a role he has held since 2023. He is based in Cambridge, Massachusetts. In this position, he is responsible for overseeing legal matters and providing guidance on regulatory compliance and corporate governance.
Board Membership at American Kidney Fund
Since 2021, Brian Krex has been a member of the Board of Trustees at the American Kidney Fund. This role involves participating in strategic decision-making and supporting initiatives aimed at improving kidney health and patient support.
Previous Experience at AGTC and Clover Biopharmaceuticals
Prior to his current role, Brian Krex worked as General Counsel at AGTC from 2019 to 2020. He then served in the same capacity at Clover Biopharmaceuticals from 2021 to 2023. In these roles, he managed legal affairs and contributed to the companies' strategic objectives.
Experience at Alexion Pharmaceuticals and Pfizer
Brian Krex held the position of Vice President, Commercial and Regulatory Law at Alexion Pharmaceuticals from 2015 to 2019. Before that, he was Assistant General Counsel at Pfizer from 2006 to 2015. His experience in these roles involved navigating complex legal and regulatory environments in the pharmaceutical industry.
Legal Career at Moses & Singer LLP
Brian Krex began his legal career as a Senior Associate at Moses & Singer LLP, where he worked from 2000 to 2006. This position provided him with foundational experience in legal practice, particularly in commercial and regulatory law.
Education and Expertise
Brian Krex holds a Juris Doctor (JD) degree, which equips him with the legal knowledge necessary for his roles in the pharmaceutical and healthcare sectors. His expertise includes commercial law, regulatory compliance, and corporate governance.